Diego Díaz García/X
May 28, 2025, 06:00
Diego Díaz García Shares OptiTROP-Lung03 Trial Results at ASCO
Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:
“OptiTROP-Lung03 ASCO
Sac-TMT shows superior efficacy vs docetaxel in pretreated EGFRm NSCLC:
- ORR 45.1% vs 15.6% (p=0.0004).
- PFS: 6.9 vs 2.8 mo (HR 0.30).
- OS: HR 0.49 (adjusted HR 0.36).
- Better safety profile.
- A potential new standard of care.”
More posts featuring Diego Díaz García.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11
May 29, 2025, 12:46